临床药师依据患者基因型参与其心脏换瓣的华法林抗凝实践被引量：1

Pharmacogenomics Based Warfarin Anticoagulation for a Patient in Cardiac Valve Replacement

下载PDF

导出

摘要本文回顾临床药师参与1例应用药物基因组学调整华法林给药的成功案例,基于药物基因组学的华法林个体化给药,为调整华法林给药剂量提供科学依据,减少传统经验给药模式的盲目性和潜在风险,增加患者依从性,提高抗凝治疗的成功率。 This article reviews a successful case of warfarin adjustment based on pharmacogenomics by clinical pharmacists. Pharmacogenomics can provide scientific basis for individualized warfarin adjustment,which can reduce the blindness of traditional practice and the potential risks, increase patients' compliance and improve the success rate of anticoagulation treatment.

作者谢浩刘俊韦俊

机构地区南京市浦口区中心医院药剂科皖南医学院弋矶山医院药剂科皖南医学院弋矶山医院胸心外科

出处《药学与临床研究》 2015年第1期71-72,共2页 Pharmaceutical and Clinical Research

基金皖南医学院中青年科研基金自然科学类项目(WK2014F20)

关键词华法林 CYP2C9 VKORC1 个体化抗凝主动脉瓣膜置换术 Warfarin CYP2C9 VKORC1 Individualized anticoagulant therapy Aortic valve replacement

分类号 R969.3 [医药卫生—药理学]

引文网络
相关文献

参考文献1

1高菲,宋洪涛,曾志勇,冯英力.CYP2C9和VKORC1基因多态性对心脏瓣膜置换术后华法林维持剂量和抗凝效果的影响[J].中国药房,2010,21(22):2053-2057. 被引量：23

二级参考文献13

1涂向东,江清华,兰风华.三种简易提取全血基因组DNA方法的比较[J].中国实验诊断学,2006,10(3):264-266. 被引量：29
2Wadelius M, Chen LY, Lindh JD, et al.The largest prospective warfarin-treated cohort supports genetic forecasting[J].Blood, 2009,113 (4) : 784.
3Aithal GP, Day CP, Kesteven PJL, et aL Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].Lancet, 1999,353 (27) : 717.
4Wadelius M, Chen LY, Erikesson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J].Hum Genet, 2007,121 ( 1 ): 23.
5Chem HD, Ueng TH, Fu YP, et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese[J].Clinica Chimiva Acta, 2006,367 (1-2) : 108.
6Wang SL, Huang JD, Lai MD, et al.Deteetion of CYP2C9 polymorphisrn based on the polymerase chain reaction in Chinese[J].Pharmacogenetics, 1995,5( 1 ) : 37.
7Sconce EA, Khan TI, Wynne HA, et al.The impact of CYP2C9 and VKORClgenetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen[J].Blood, 2005,106 (7) :2 329.
8Sanderson S, Emery J, Higgins J.CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis[J].Genet Med,2005,7(2) :97.
9Wang TL, Li HL, Tjong WY, et al.Genetic factors contribute to patient-specific warfarin dose for Han Chinese[J]. Clinica Chimica Acta, 2008,396 ( 1 - 2) : 76.
10Yuan HY, Chen JJ, Lee MT, et al.A noval functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity[J]. Hum Mol Gene, 2005,14(3) : 1 745.